secwatch.observer — SEC 8-K summary
======================================

Issuer:     AN2 Therapeutics, Inc. (ANTX)
CIK:        0001880438
Form:       8-K
Filed at:   2026-03-17T23:59:59+00:00
Accession:  0001193125-26-110681
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AN2 Therapeutics reports FY2025 net loss of $35.2M; $40M private placement extends runway into 2029
--------------------------------------------------------------------------------

- Net loss for FY2025 was $35.2 million, compared to $51.3 million in FY2024.
- Cash and investments at Dec 31, 2025: $60.0 million; private placement in March 2026 added ~$40 million gross.
- Phase 2 study of oral epetraborole in polycythemia vera to begin 3Q26; data readouts possible from 4Q26.
- Phase 2 investigator-initiated trial in M. abscessus lung disease enrollment expected 1Q26; topline late 2027.
- Phase 1 first-in-human trial of AN2-502998 for Chagas nearing completion; initial data expected 1Q26.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1880438/000119312526110681/0001193125-26-110681-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1880438/000119312526110681/antx-20260317.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-110681

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer